Replimune Group, Inc.
Financial highlights
| Metric | FY 03/31/26 | FY 03/31/25 | FY 03/31/24 | FY 03/31/23 | FY 03/31/22 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Selling, general & administrative | $98.7M | $72.2M | — | — | — |
| Research and development | $221.2M | $189.4M | $175.0M | $126.5M | $79.5M |
| Operating expenses | $319.9M | $261.6M | $234.8M | $177.1M | $118.3M |
| Operating income | -$319.9M | -$261.6M | -$234.8M | -$177.1M | -$118.3M |
| Pretax income | -$314.5M | -$246.8M | -$215.4M | -$174.0M | -$118.0M |
| Income tax expense | -$551,000 | $468,000 | $408,000 | $288,000 | $0 |
| Net income | -$313.9M | -$247.3M | -$215.8M | -$174.3M | -$118.0M |
| Balance Sheet | |||||
| Cash and equivalents | $209.0M | $111.1M | $74.5M | $146.6M | $105.9M |
| Current assets | $279.1M | $495.9M | $433.7M | $592.6M | $404.0M |
| Total assets | $332.4M | $551.3M | $487.7M | $646.6M | $461.2M |
| Current liabilities | $58.2M | $62.4M | $40.4M | $33.8M | $20.8M |
| Total liabilities | $166.2M | $135.5M | $113.2M | $91.3M | $50.0M |
| Stockholders' equity | $166.2M | $415.8M | $374.5M | $555.3M | $411.2M |
| Cash Flow Statement | |||||
| Cash from operations | -$280.3M | -$192.2M | -$185.5M | -$128.1M | -$82.2M |
| Depreciation and amortization | $3.3M | $3.5M | $2.7M | $2.4M | $2.1M |
| Stock-based compensation | $32.3M | $35.0M | $34.1M | $28.1M | $24.3M |
| Capital expenditure | $4.2M | $6.7M | $5.7M | $2.3M | $2.3M |
| Free cash flow | -$284.6M | -$198.9M | -$191.1M | -$130.3M | -$84.5M |
| Impairments | $188,000 | $0 | — | — | — |
Shares outstanding 82.6M · Free float 81.6%
Annual filing data through FY ended March 31, 2026; float as of July 15, 2026.